Torsten Haferlach Leukemia Diagnostics Foundation and Illumina donate sequencing equipment to Latin American laboratories

Next-Generation Sequencing (NGS) has revolutionized the diagnostics and therapy of acute myeloid leukemia (AML). "It is time for us to come together to tackle the important tasks in patient care and to make the best possible use of global advances in technology for our patients", says MLL founder and CEO Prof. Dr. Dr. Torsten Haferlach. That is why his foundation, the Torsten Haferlach Leukemia Diagnostics Foundation, together with Illumina, is donating six iSeq™ instruments to reference laboratories in Latin America so that low to middle-income countries can also advance AML diagnostics and therapy. The donation is directed to five Latin American countries - Chile, Peru, Paraguay, Uruguay and Brazil - which are part of the International Consortium on Acute Leukemia (ICAL). In addition to Prof. Torsten Haferlach, the project will be led by Prof. Dr. Peter Valk of the Erasmus University Medical Centre in Rotterdam.

The American Society of Hematology (ASH) and Illumina have published all information about this donation project in recent press releases:

ASH Announces Donation of Next-Generation Sequencing Equipment to Countries in the International Consortium on Acute Leukemia (ASH)

Transforming Diagnoses and Care for Acute Myeloid Leukemia (Illumina)